UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2020

 

Commission File Number 000-20181

 

SAPIENS INTERNATIONAL CORPORATION N.V.

(Translation of Registrant’s name into English)

 

Azrieli Center

26 Harokmim St.

Holon, 5885800 Israel

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒         Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

CONTENTS

 

Exhibit No.   Title of Exhibit
99.1   Press Release

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Sapiens International Corporation N.V.

(Registrant)

     
Date: May 14, 2020 By:  /s/ Roni Giladi
    Roni Giladi
    Chief Financial Officer

 

 

2

 

 

Exhibit 99.1

 

 

Sapiens Reports First Quarter 2020 Financial Results

and Announces a Cash Dividend of $0.14 Per Share

 

Holon, Israel, May 14, 2020 – Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, and a member of the Formula Group (NASDAQ: FORTY and TASE: FORT), today announced its financial results for the first quarter ended March 31, 2020.

 

Summary Results for First Quarter 2020 (USD in millions, except per share data)

 

    GAAP           Non-GAAP        
    March 31,
2020
    March 31,
2019
    % Change     March 31,
2020
    March 31,
2019
    % Change  
Revenue   $ 90.5     $ 76.8       17.9 %   $ 90.5     $ 76.8       17.9 %
Gross Profit   $ 36.3     $ 29.8       21.7 %   $ 39.8     $ 33.1       20.2 %
Gross Margin     40.1 %     38.8 %     130 bps       44.0 %     43.1 %     90 bps  
Operating Income   $ 10.3     $ 8.1       27.3 %   $ 14.6     $ 11.8       24.4 %
Operating Margin     11.4 %     10.5 %     90 bps       16.1 %     15.3 %     80 bps  
Net income (*)   $ 6.8     $ 5.2       32.3 %   $ 10.4     $ 8.4       24.1 %
Diluted EPS   $ 0.13     $ 0.10       30 %   $ 0.20     $ 0.17       17.6 %

 

(*) Attributable to Sapiens’ shareholders

 

“Sapiens’ first-quarter performance reflects our continued focus on supporting our existing customers and closing new business,” said Roni Al-Dor, president and CEO, Sapiens. “On a non-GAAP basis, we reported 17.9% revenue growth and increased operating margins by 80 basis points to 16.1%, with both P&C and L&A contributing to growth in the quarter."

 

“In March, we responded to the COVID-19 global outbreak per country, controlling expenses where appropriate, while maintaining productivity. I'm incredibly proud of my teams' accomplishments in this unique and challenging environment, and impressed by our customers’ rapid shift to remote work, while they remained committed to their customers and their own digital transformation projects. As a result, Sapiens maintained momentum through the quarter,” said Al-Dor.

 

Continued Al-Dor: “Across all our product lines, we see a growing demand for managed services, which is a testament to our delivery model – it allows carriers to focus on running their business. The current business disruption highlights the need for legacy insurance companies to migrate their platforms and increase their relevancy with more digital solutions. Our recent acquisition in Germany, sum.cumo, expands our digital offerings, helping us become even more competitive. While there continues to be uncertainty resulting from COVID-19, we remain focused on executing our long-term strategy. I am confident that as the global economy recovers, Sapiens will emerge stronger and well- positioned for continued growth.”

 

“Strong demand for our digital products, combined with high recurring revenue and a solid balance sheet, position us for success in this challenging environment. We’ve taken appropriate actions to provide the necessary flexibility for revenue growth and operating efficiency within the current circumstances. While our business remains strong, due to macro events there could be delays in closing new deals, which could slightly impact our revenue. Therefore, we are slightly revising our annual revenue guidance for 2020 to the range of $368 million to $377 million, as compared to our prior range of $377 million to $383 million. Overall, we changed the mid-point of the revenue guidance by 2.0%. Sapiens’ guidance for annual operating margin remains unchanged at 16.0% to 16.5%,” said Al-Dor.

 

“Furthermore, Sapiens remains committed to returning value to shareholders,” concluded Al-Dor. “Despite the condition in the market, we announce a dividend of $0.14 per share – approximately $7 million – reflecting our continued confidence in our business and Sapiens’ ability to generate cash.”

 

1

 

 

The dividend will be paid on June 10, 2020 to Sapiens Shareholders of record as of May 27, 2020.

 

The prospective dividend is subject to withholding tax at source, under the Israeli Tax law, at the rate of 25% of the dividend amount payable to each shareholders of record.

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast on May 14, 2020 at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results.

 

Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

 

North America (toll-free): + 1-888-407-2553; International: +972-3-918-0610; UK: 0-800-917-9141

 

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations/

 

If you are unable to join live, a replay of the call will be accessible until May 23, 2020, as follows:

 

North America: 1-888-326-9310; International: +972-3-925-5925

 

A recorded version of the webcast will also be available via the Sapiens website, for three months at the same location.

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP operating income, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

2

 

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation,  restructuring and cost reduction costs, tax adjustments related to non-GAAP adjustments, and acquisition-related costs, which pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

3

 

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Adjusted EBITDA as net profit, adjusted for stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, financial and other expenses, and provision for income taxes. These amounts are often excluded by other companies to help investors understand the operational performance of their business.

 

The Company defines Adjusted EBITDA as net profit, adjusted for valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies to help investors understand the operational performance of their business.

 

The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back payments related to investment in the new campus in India, cash payments made for former acquisitions in respect of  future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

4

 

 

About Sapiens

 

Sapiens International Corporation empowers insurers to succeed in an evolving industry. The company offers digital software platforms, solutions and services for the property and casualty, life, pension and annuity, reinsurance, financial and compliance, workers’ compensation and financial markets. With more than 35 years of experience delivering to over 450 organizations globally, Sapiens has a proven ability to satisfy customers’ core, data and digital requirements. For more information: www.sapiens.com

 

Forward Looking Statement

 

Some of the statements in this press release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities and Exchange Act of 1934 and the United States Private Securities Litigation Reform Act of 1995. Words such as “will,” “expects,” “believes” and similar expressions are used to identify these forward-looking statements (although not all forward-looking statements include such words). These forward-looking statements, which may include, without limitation, projections regarding our future performance and financial condition, are made on the basis of management’s current views and assumptions with respect to future events. Any forward-looking statement is not a guarantee of future performance and actual results could differ materially from those contained in the forward-looking statement.

 

These statements speak only as of the date they were made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We operate in a changing environment. New risks emerge from time to time and it is not possible for us to predict all risks that may affect us. For more information regarding these risks and uncertainties, as well as certain additional risks that we face, please refer to the Risk Factors detailed in Item 3 of Part III of our Annual Report on Form 20-F for the year ended December 31, 2018, and subsequent reports and registration statements filed from time to time with the Securities and Exchange Commission.

 

Investors and Media Contact

 

Brett Mass

Managing Partner

Hayden IR

Phone: +1 646-536-7331

Email: Brett.Masss@HaydenIR.com

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended  
    March 31,  
    2020     2019  
    (unaudited)     (unaudited)  
             
Revenue     90,534       76,787  
Cost of revenue     54,270       46,980  
                 
Gross profit     36,264       29,807  
                 
Operating expenses:                
Research and development, net     10,526       8,777  
Selling, marketing, general and administrative     15,460       12,953  
Total operating expenses     25,986       21,730  
                 
Operating income     10,278       8,077  
                 
Financial and other expenses, net     1,487       1,054  
Taxes on income     1,901       1,847  
                 
Net income     6,890       5,176  
                 
Attributed to non-controlling interest     70       21  
                 
Net income attributable to Sapiens’ shareholders     6,820       5,155  
                 
Basic earnings per share     0.14       0.10  
                 
Diluted earnings per share     0.13       0.10  
                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     50,175       49,986  
                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     51,083       50,329  

 

 

6

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED NON-GAAP STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended  
    March 31,  
    2020     2019  
    (unaudited)     (unaudited)  
             
Revenue     90,534       76,787  
Cost of revenue     50,743       43,683  
                 
Gross profit     39,791       33,104  
                 
Operating expenses:                
Research and development, net     11,963       10,169  
Selling, marketing, general and administrative     13,214       11,185  
Total operating expenses     25,177       21,354  
                 
Operating income     14,614       11,750  
                 
Financial and other expenses, net     1,487       1,054  
Taxes on income     2,645       2,285  
                 
Net income     10,482       8,411  
                 
Attributable to non-controlling interest     70       21  
                 
Net income attributable to Sapiens’ shareholders     10,412       8,390  
                 
Basic earnings per share     0.21       0.17  
                 
Diluted earnings per share     0.20       0.17  
                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     50,175       49,986  
                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     51,083       50,329  

 

7

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

    Three months ended  
    March 31,  
    2020     2019  
    (unaudited)     (unaudited)  
             
GAAP gross profit     36,264       29,807  
Amortization of capitalized software     1,496       1,341  
Amortization of other intangible assets     2,031       1,956  
Non-GAAP gross profit     39,791       33,104  
                 
GAAP operating income     10,278       8,077  
Gross profit adjustments     3,527       3,297  
Capitalization of software development     (1,437 )     (1,392 )
Amortization of other intangible assets     589       535  
Stock-based compensation     622       453  
Acquisition-related costs *)     1,035       780  
Non-GAAP operating income     14,614       11,750  
                 
GAAP net income attributable to Sapiens’ shareholders     6,820       5,155  
Operating income adjustments     4,336       3,673  
Taxes on income     (744 )     (438 )
Non-GAAP net income attributable to Sapiens’   shareholders     10,412       8,390  

 

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

8

 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

    Q1 2020     Q4 2019     Q3 2019     Q2 2019     Q1 2019  
                               
Revenues     90,534       86,715       82,643       79,529       76,787  
Gross profit     39,791       38,402       36,712       34,794       33,104  
Operating income     14,614       14,345       13,530       12,581       11,750  
Net income to Sapiens’ shareholders     10,412       10,553       10,412       9,541       8,390  
Adjusted EBITDA     15,724       15,271       14,523       13,358       12,524  
                                         
Basic earnings per share     0.21       0.21       0.21       0.19       0.17  
Diluted earnings per share     0.20       0.21       0.21       0.19       0.17  

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

    Q1 2020     Q4 2019     Q3 2019     Q2 2019     Q1 2019  
                               
North America     44,567       41,787       44,413       39,216       38,149  
Europe     40,232       37,504       30,273       33,881       32,193  
Rest of the world     5,735       7,424       7,957       6,432       6,445  
                                         
Total     90,534       86,715       82,643       79,529       76,787  

 

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

    Q1 2020     Q4 2019     Q3 2019     Q2 2019     Q1 2019  
                               
Cash-flow from operating activities     5,759       21,429       18,671       15,507       10,550  
Increase in capitalized software development costs     (1,437 )     (1,162 )     (1,541 )     (1,570 )     (1,392 )
Capital expenditures     (552 )     (2,456 )     (973 )     (1,079 )     (641 )
Capital expenditures related to new campus in India     -       -       (6,325 )     -       -  
Free cash-flow     3,770       17,811       9,832       12,858       8,517  
                                         
Capital expenditures related to new campus in India     -       -       6,325       -       -  
Cash payments attributed to acquisition-related costs(*) (**)     737       200       100       1,692       1,608  
                                         
Adjusted free cash-flow     4,507       18,011       16,257       14,550       10,125  

 

(*) Included in cash-flow from operating activities

 

(**) Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.


 

9

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

    Three months ended  
    March 31,  
    2020     2019  
    (unaudited)     (unaudited)  
             
GAAP operating income     10,278       8,077  
                 
Non-GAAP adjustments:                
Amortization of capitalized software     1,496       1,341  
Amortization of other intangible assets     2,620       2,491  
Capitalization of software development     (1,437 )     (1,392 )
Stock-based compensation     622       453  
Compensation related to acquisition and acquisition-related costs     1,035       780  
                 
Non-GAAP operating income     14,614       11,750  
                 
Depreciation     1,110       773  
                 
Adjusted EBITDA     15,724       12,523  

 

10

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

    March 31,     December 31,  
    2020     2019  
    (unaudited)     (unaudited)  
             
ASSETS            
             
CURRENT ASSETS            
Cash and cash equivalents     79,557       66,295  
Trade receivables, net and unbilled receivables     59,958       50,221  
Investment in restricted deposit     -       22,890  
Other receivables and prepaid expenses     8,105       7,817  
                 
Total current assets     147,620       147,223  
                 
LONG-TERM ASSETS                
Property and equipment, net     16,657       16,601  
Severance pay fund     4,949       5,106  
Goodwill and intangible assets, net     246,676       228,691  
Operating lease right-of-use assets     45,872       49,539  
Other long-term assets     6,549       5,261  
                 
Total long-term assets     320,703       305,198  
                 
TOTAL ASSETS     468,323       452,421  
                 
LIABILITIES AND EQUITY                
                 
CURRENT LIABILITIES                
Trade payables     5,650       5,107  
Current maturities of Series B Debentures     9,898       9,898  
Short-term bank loan     20,000       -  
Accrued expenses and other liabilities     62,886       60,574  
Current maturities of operating lease liabilities     7,920       8,312  
Deferred revenue     22,797       21,021  
                 
Total current liabilities     129,151       104,912  
                 
LONG-TERM LIABILITIES                
Series B Debentures, net of current maturities     48,985       58,850  
Deferred tax liabilities     7,094       5,082  
Other long-term liabilities     7,975       8,321  
Long-term operating lease liabilities     40,945       43,394  
Accrued severance pay     6,319       6,364  
                 
Total long-term liabilities     111,318       122,011  
                 
EQUITY     227,854       225,498  
                 
TOTAL LIABILITIES AND EQUITY     468,323       452,421  

 

11

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

    For the three months ended March 31,  
    2020     2019  
    (unaudited)     (unaudited)  
Cash flows from operating activities:            
Net income     6,890       5,176  
Reconciliation of net income to net cash provided by operating
activities:
               
Depreciation and amortization     5,226       4,605  
Accretion of discount on Series B Debentures     33       39  
Stock-based compensation related to options issued to employees     622       453  
                 
Net changes in operating assets and liabilities, net of amount acquired:                
Trade receivables, net and unbilled receivables     (9,009 )     (4,194 )
Deferred tax assets, net     (1,257 )     (855 )
Other operating assets     2,260       328  
Trade payables     (52 )     (426 )
Other operating liabilities     (759 )     1,247  
Deferred revenues     1,655       4,167  
Accrued severance pay, net     150       10  
                 
Net cash provided by operating activities     5,759       10,550  
                 
Cash flows from investing activities:                
Purchase of property and equipment     (552 )     (641 )
Investment in deposit     (665 )     (1,106 )
Proceeds from restricted deposit used for completed acquisition     22,890       -  
Payments for business acquisitions, net of cash acquired     (22,061 )     -  
Capitalized software development costs     (1,437 )     (1,392 )
                 
Net cash used in investing activities     (1,825 )     (3,139 )
                 
Cash flows from financing activities:                
Proceeds from employee stock options exercised     600       17  
Repayment of Series B Debenture     (9,898 )     (9,898 )
Receipt of short-term loan     20,000       -  
Repayment of loan     -       (2 )
Payment of contingent considerations     (538 )     (58 )
Dividend to non-controlling interest     -       (66 )
                 
Net cash used in financing activities     10,164       (10,007 )
                 
Effect of exchange rate changes on cash and cash equivalents     (836 )     1,352  
                 
Increase (decrease) in cash and cash equivalents     13,262       (1,244 )
Cash and cash equivalents at the beginning of period     66,295       64,628  
                 
Cash and cash equivalents at the end of period     79,557       63,384  

 

12

 

 

Debentures Covenants

 

As of March 31, 20120, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures that it issued in September 2017, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

§ Target shareholders’ equity (excluding minority interest): above $120 million.
     
§ Actual shareholders’ equity equal to $226 million.

 

Covenant 2

 

§ Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
     
§ Actual ratio of net financial indebtedness to net capitalization equal to (0.08)%.

 

Covenant 3

 

§ Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
     
§ Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (0.003).

 

 

13